02.09.2025 • News

Jungbunzlauer Acquires Illinois Plant to Establish US Manufacturing

Jungbunzlauer to acquire from International Flavors & Fragrances (IFF) a multipurpose site in Thomson, IL, establishing a US manufacturing footprint.

Jungbunzlauer, a manufacturer of sustainable ingredients from natural sources, announced today the signing of a binding and definitive agreement to acquire the multipurpose production site in Thomson, IL, from International Flavors & Fragrances (IFF).

“This acquisition is an important step in delivering on our strategic capacity expansion in North America,” said Bruno Tremblay, Chief Executive Officer of Jungbunzlauer. “Establishing a US manufacturing footprint allows us to work closer to many of our US customers, better understand their challenges, and deliver solutions that truly make a difference.”

The asset deal does not include any of IFF’s commercial business, product lines, or employees, and the terms of the deal were not disclosed.

“Upon closing the transaction, our immediate focus will be on preparing the site for our specific production needs,” added Tremblay. “As we finalise our operational plans, we look forward to sharing updates, including information about future hiring.”

The transaction is expected to close in early Q4 2025, subject to receipt of all applicable regulatory approvals and the satisfaction of other customary closing conditions.

Jungbunzlauer
Jungbunzlauer establishes a US manufacturing footprint, further strengthening its North American presence in addition to its existing Canadian sites.
© Adobe Stock

Company

Logo:

Jungbunzlauer International AG

Aeschengraben 27
4051 Basel
Switzerland

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read